Steve Bryson, PhD,  science writer—

Various social and environmental factors in different locations across the U.S. influenced a decline in lung function among adolescents and young adults with cystic fibrosis (CF), a large-scale analysis demonstrated. CF patients with early lung function decline tended to live in areas with more social-environmental adversity, such as higher…

The total cost of managing cystic fibrosis (CF) — healthcare costs, patient and caregiver costs, as well as costs to society — varied widely per patient per year in a review of published studies. Most studies only reported costs to the healthcare system, such as hospitalizations and healthcare visits,…

At-home telemonitoring of lung function in children with cystic fibrosis (CF) can detect the early onset of pulmonary exacerbations, or a sudden worsening of lung symptoms, and may help in determining the likelihood of a child’s response to treatment, a study reported. Its researchers proposed thresholds for lung function…

Fas, a protein that triggers programmed cell death, was identified as a potential urinary biomarker for kidney injury associated with certain antibiotics used to treat lung infections in people with cystic fibrosis (CF), a new study shows. To identify Fas as a biomarker, researchers used a three-dimensional cell-based system…

Cough and sputum symptoms in adults with cystic fibrosis (CF), as assessed by the Cough and Sputum Assessment Questionnaire (CASA-Q), were significantly linked to impaired quality of life, according to a pilot study. Worse cough and sputum symptoms occurred more often in women, those with severe shortness of breath…

Blocking iron-dependent cell death, a process called ferroptosis, may treat antibiotic-resistant Pseudomonas aeruginosa lung infections in people with cystic fibrosis (CF). “Blocking ferroptosis might be a really promising and unique new way to treat [Pseudomonas aeruginosa] infections,” said Peter A. Jorth, PhD, from Cedars-Sinai Medical Center, California,…

Long-term Trikafta treatment led to sustained improvements in CFTR function and reduced lung symptoms in children, ages 6-11, with cystic fibrosis (CF), according to almost three years of interim data from an open-label extension (OLE) study. There were no signs of lung function decline during the 3.5-year treatment…

Sionna Therapeutics’ second-generation molecules, combined with standard CFTR modulators, fully restored the production and function of the CFTR protein with the most common mutation that causes cystic fibrosis (CF), according to preclinical data. The Series 2 molecules, SION-719 and SION-451, are undergoing investigational new drug (IND) enabling…

A high degree of genetic diversity was found among strains of Pseudomonas aeruginosa bacteria initially infecting the lungs of people with cystic fibrosis (CF), a study reports. Over a seven-year follow-up, the majority of CF patients experience a recurrence of the bacteria, with one-third of those being infected…

All the cystic fibrosis (CF) patients participating in the Phase 2 portion of a clinical trial have been dosed with BX004, an inhaled virus-based therapy for chronic Pseudomonas aeruginosa bacterial infections of the lungs. Data from the first part of the Phase 1b/2a study (NCT05010577) showed the…